J. Safra Sarasin Holding AG Has $2.89 Million Position in IQVIA Holdings Inc. $IQV

J. Safra Sarasin Holding AG grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 174.3% during the fourth quarter, HoldingsChannel reports. The firm owned 12,827 shares of the medical research company’s stock after buying an additional 8,151 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in IQVIA were worth $2,891,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its holdings in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC increased its stake in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of IQVIA during the 2nd quarter worth about $514,000. Advisors Asset Management Inc. boosted its stake in IQVIA by 15.5% during the 2nd quarter. Advisors Asset Management Inc. now owns 6,729 shares of the medical research company’s stock valued at $1,060,000 after purchasing an additional 903 shares during the period. Finally, Choreo LLC grew its holdings in IQVIA by 29.8% in the 2nd quarter. Choreo LLC now owns 4,815 shares of the medical research company’s stock valued at $759,000 after buying an additional 1,106 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV opened at $170.50 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a 50-day moving average price of $184.00 and a 200 day moving average price of $205.18. The firm has a market capitalization of $28.93 billion, a PE ratio of 21.69, a price-to-earnings-growth ratio of 1.60 and a beta of 1.39. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Morgan Stanley set a $240.00 price target on IQVIA in a report on Wednesday, February 11th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. Finally, UBS Group cut their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.